Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
0.8610
-0.0511 (-5.60%)
Jul 13, 2026, 10:49 AM EDT - Market open
CELZ Revenue
Creative Medical Technology Holdings had revenue of $3.00K in the twelve months ending March 31, 2026, down -78.57% year-over-year. In the year 2025, Creative Medical Technology Holdings had annual revenue of $6.00K, down -45.45%.
Revenue (ttm)
$3.00K
Revenue Growth
-78.57%
P/S Ratio
1,123.91
Revenue / Employee
$750
Employees
4
Market Cap
3.18M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.00K | -5.00K | -45.45% |
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | 165.50K | 41.10K | 33.04% |
| Dec 31, 2018 | 124.40K | 119.60K | 2,491.67% |
| Dec 31, 2017 | 4.80K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCELZ News
- 12 days ago - Creative Medical Technology Holdings Issues Mid-Year Update - GlobeNewsWire
- 12 days ago - Creative Medical announces agreements for exercise of warrants for $4.5M - TheFly
- 12 days ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds - GlobeNewsWire
- 13 days ago - Why Did Penny Stock Creative Medical Technology Holdings (CELZ) Rocket Higher Today? - TipRanks
- 17 days ago - Creative Medical files to sell 3.05M shares of common stock - TheFly
- 21 days ago - Creative Medical expands ADAPT trial under new FDA clearance - TheFly
- 21 days ago - Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain - GlobeNewsWire
- 27 days ago - Creative Medical launches national veteran data collection for Project PHOENIX - TheFly